

Buscar no portal



envelope icon (https://webmail7.anvisa.gov.br/owa) questions (perguntas-frequentes) | Legislation (legislacao) | Contact (contato) | services (servicos) | Press (area-de-imprensa)

MENU

RSS (http://portal.anvisa.gov.br/noticias/rss?p\_p\_cacheability=cacheLevelFull) Print

MEDICINE

# Gout patients gain new treatment

The new drug Zurampic® (lesinurade) approved by Anvisa treats patients over 18 years with high uric acid levels in the blood

Published: 09/26/2016 10:02  
Last Modified: 26/09/2016 10:16

tweet (https://twitter.com/share)

Compartilhar 0

The treatment of gout has a new alternative from now. Anvisa approved a new drug, Zurampic® ( lesinurade ), which is indicated for the treatment of hyperuricemia associated with gout in combination with a xanthine oxidase inhibitor in patients over 18 years.

Gout is a metabolic condition that, in most patients, is the result of inadequate excretion of uric acid leading to hyperuricemia and deposition of urate crystals in body tissues.

The drug will be manufactured by Hovione Limited company located in Ireland and the drug registration holder in Brazil will be the company Astrazeneca Brazil Ltda.

### drug action

Combination therapy with lesinurade and a xanthine oxidase inhibitor and acts both excretion as in the production of uric acid, providing a dual mechanism of approach effectively reduces serum uric acid and allows a significantly higher number of patients to achieve and maintain the goals treatment for disease control.

### Priority for unpublished

Anvisa has given priority to new drugs analysis in the country to increase the treatment options available. Thus, unpublished novel medicines or generics can enter the market in less time. Recently, for example, the Agency adopted a new biological product for the treatment of hemophilia (http://portal.anvisa.gov.br/noticias?p\_p\_id=101\_INSTANCE\_FXrxp9qY7FbU&\_101\_INSTANCE\_FXrxp9qY7FbU\_groupId=219201&\_101\_INSTANCE\_FXrxp9qY7FbU\_ufTitle=anvisa-aprova-novo-produto-biologico-para-hemofilia&\_101\_INSTANCE\_FXrxp9qY7FbU\_struts\_action=%2Fasset\_publisher%2Fview\_content&\_101\_INSTANCE\_FXrxp9qY7FbU\_assetEntryId=2951462&\_101\_INSTANCE\_FXrxp9qY7FbU\_type=content)

new drug (http://portal.anvisa.gov.br/noticias?p\_p\_id=101\_INSTANCE\_FXrxp9qY7FbU&p\_p\_lifecycle=0&p\_p\_state=normal&p\_p\_mode=view&p\_p\_col\_id=column-2&p\_p\_col\_count=1&p\_r\_p\_564233524\_tag=novo+medicamento) retreatment (http://portal.anvisa.gov.br/noticias?p\_p\_id=101\_INSTANCE\_FXrxp9qY7FbU&p\_p\_lifecycle=0&p\_p\_state=normal&p\_p\_mode=view&p\_p\_col\_id=column-2&p\_p\_col\_count=1&p\_r\_p\_564233524\_tag=novo+tratamento) drop (http://portal.anvisa.gov.br/noticias?p\_p\_id=101\_INSTANCE\_FXrxp9qY7FbU&p\_p\_lifecycle=0&p\_p\_state=normal&p\_p\_mode=view&p\_p\_col\_id=column-2&p\_p\_col\_count=1&p\_r\_p\_564233524\_tag=gota) uric acid (http://portal.anvisa.gov.br/noticias?p\_p\_id=101\_INSTANCE\_FXrxp9qY7FbU&p\_p\_lifecycle=0&p\_p\_state=normal&p\_p\_mode=view&p\_p\_col\_id=column-2&p\_p\_col\_count=1&p\_r\_p\_564233524\_tag=%C3%A1cido+%C3%BArico)

Back to the top!

(http://www.youtube.com/user/anvisaoficial)

(https://twitter.com/anvisa\_oficial)